Table 3.
Antibiotic Resistance Rates of Helicobacter pylori in Korea and the United States since 2015
| Antibiotic | Korea | United States | |||
|---|---|---|---|---|---|
| Primary, % | Secondary, % | Primary, % | Secondary, %* | ||
| Clarithromycin | 17.8–45.9 | 78.0 | 30.0 | 70.6 | |
| Metronidazole | 29.5–43.2 | 51.2 | 33.3 | 79.4 | |
| Levofloxacin | 37.0–62.2 | 70.7 | 29.6 | 42.9† | |
| Tetracycline | 12.7–16.2 | 12.2 | 0.5 | 0.0 | |
| Amoxicillin | 5.6–9.5 | 17.1 | 1.1 | 0.0 | |
| Rifabutin | 0–3 | - | 0.5 | - | |
*Antibiotic susceptibility test (AST) results in patients who failed two or more H. pylori eradication therapies between 2010 and 2017; †AST result for ciprofloxacin.